Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1985)	4/14/2003 10:55:31 AM
From: nigel bates	Read Replies (1) \| Respond to of 2243

I note GPC made firework status today. Xenova had a pretty decent day in the UK (and has traded all of 5k in the US...) - uk.finance.yahoo.com on a couple of announcements - Message 18836972 Message 18836974 Trickled a little of my OGS money into them.

To: Icebrg who wrote (1985)	5/2/2003 4:41:10 PM
From: Icebrg	Read Replies (2) \| Respond to of 2243

>> Cortex Pharmaceuticals COR >> is one of my moonshoot candidates. Over the last couple of days they have had a kind of blast-off. From 0.81 on 23.4 with a close of 1.46 today for a gain of about 80 %. Market cap. is still a paltry 25 mUSD. According NeuroInvestment the main reason for the move has been a roadshow featuring Gary Lynch - one of the company's founders and scientific engines. The most recent part of the surge might also have been helped by the fact that Dr. Tracy had some nice words to say about the company in the May issue of his newsletter. I have btw. the stock included in my stock contest portfolio at a cost of 0.61. It helps in keeping up the numbers. Erik

To: Icebrg who wrote (1985)	5/2/2003 6:54:41 PM
From: Icebrg	Read Replies (1) \| Respond to of 2243

>> Spectrum Pharmaceuticals (SPPI)>> And while I am touching on the combination of moon-shots and Dr Tracy. Our NeuroInvestor also suggested - in the May issue reviewing current and potential future schizophrenia treatments - that Spectrum might salvage some parts of the left-overs from Dr. Glasky's NeoTherapeutic's era. In this particular case NEO-356 for which compound there appears to be some in-licensing interest from a couple of midsize pharma types. Any such move would of course be of immense interest to Spectrum (market cap. 6 mUSD) and its shareholders. In Spectrum's situation every dollar will count. De-listing is still a very real threat. Erik